IRIS
LAVATELLI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.836
AS - Asia 2.101
EU - Europa 1.841
SA - Sud America 232
AF - Africa 37
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.053
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.779
CN - Cina 1.064
IE - Irlanda 547
SG - Singapore 512
HK - Hong Kong 261
RU - Federazione Russa 259
FI - Finlandia 235
DE - Germania 225
BR - Brasile 188
IT - Italia 158
UA - Ucraina 116
GB - Regno Unito 82
VN - Vietnam 75
IN - India 48
SE - Svezia 42
FR - Francia 35
CA - Canada 32
JP - Giappone 31
ES - Italia 25
PL - Polonia 24
TR - Turchia 22
MX - Messico 18
BD - Bangladesh 17
ZA - Sudafrica 17
AR - Argentina 16
NL - Olanda 15
AT - Austria 13
BE - Belgio 12
MA - Marocco 11
LT - Lituania 10
IQ - Iraq 9
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
PK - Pakistan 7
VE - Venezuela 7
KR - Corea 6
EC - Ecuador 5
HU - Ungheria 5
ID - Indonesia 5
AZ - Azerbaigian 4
CO - Colombia 4
IR - Iran 4
PE - Perù 4
PT - Portogallo 4
UY - Uruguay 4
AU - Australia 3
CH - Svizzera 3
CL - Cile 3
JO - Giordania 3
LK - Sri Lanka 3
MY - Malesia 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AL - Albania 2
BG - Bulgaria 2
EE - Estonia 2
ET - Etiopia 2
EU - Europa 2
GR - Grecia 2
KG - Kirghizistan 2
LV - Lettonia 2
MD - Moldavia 2
MN - Mongolia 2
RO - Romania 2
RS - Serbia 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
AM - Armenia 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
IL - Israele 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
ML - Mali 1
MU - Mauritius 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SN - Senegal 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
UG - Uganda 1
VC - Saint Vincent e Grenadine 1
VG - Isole Vergini Britanniche 1
Totale 7.053
Salva come PNG Salva come JPEG
Città #
Dublin 547
Chandler 439
Dallas 300
Singapore 269
Beijing 264
Hong Kong 259
Ashburn 255
Jacksonville 186
Nanjing 179
Helsinki 118
Boardman 112
Nanchang 84
Los Angeles 80
Princeton 80
Lawrence 77
Wilmington 72
Medford 71
Munich 62
New York 59
Shenyang 56
Hebei 55
Moscow 45
Jiaxing 44
Changsha 42
Shanghai 39
Ann Arbor 38
Hangzhou 38
Buffalo 37
Pavia 36
Ho Chi Minh City 33
Tianjin 32
Redondo Beach 31
Tokyo 26
São Paulo 23
Turku 23
Milan 20
Norwalk 20
Santa Clara 20
Warsaw 19
Woodbridge 18
Hanoi 17
Piscataway 16
Johannesburg 15
Poplar 15
The Dalles 15
Ankara 14
Boston 14
Orem 14
Denver 13
London 13
San Francisco 13
Avellino 12
Brussels 12
Chennai 12
Montreal 12
Atlanta 11
Brooklyn 11
Chicago 11
Fairfield 11
Rio de Janeiro 11
Seattle 11
Stockholm 11
Falkenstein 10
Frankfurt am Main 10
Charlotte 9
Washington 9
Phoenix 8
Toronto 8
Amsterdam 7
Houston 7
Mexico City 7
Verona 7
Campina Grande 6
Chandigarh 6
Dhaka 6
Jinan 6
Manchester 6
Ningbo 6
Nuremberg 6
Redwood City 6
Vienna 6
Belo Horizonte 5
Curitiba 5
Kenitra 5
Pune 5
Rome 5
Taizhou 5
Tamm 5
Baku 4
Bari 4
Budapest 4
Caracas 4
Columbus 4
Dearborn 4
Des Moines 4
Formia 4
Guangzhou 4
Guarulhos 4
Kunming 4
Shijiazhuang 4
Totale 4.711
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 176
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 145
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 127
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 119
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 110
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 110
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 108
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 106
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 106
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 104
AMICA: an electronic patient record specifically designed for an amyloidosis network 103
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 103
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 102
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 98
Biochemical markers in early diagnosis and management of systemic amyloidoses 97
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 96
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 96
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 96
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 95
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 95
A practical approach to the diagnosis of systemic amyloidoses 94
Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms 94
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 93
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 93
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 92
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 92
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 92
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 91
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 91
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 91
AMICA: an electronic patient record specifically designed for an amyloidosis network. 90
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 90
Prognostication of survival and progression to dialysis in AA amyloidosis 87
A workflow management system for the biological samples exchange within the amyloidosis network 87
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 85
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 85
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 85
IceTrack: a biobank information management system maximizing flexibility and usability 85
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 83
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 83
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 82
Changes in tissue proteome associated with ATTR amyloidosis: Insights into pathogenesis 81
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis 80
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 79
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 79
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 78
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 77
A workflow management system for the biological samples exchange within the amyloidosis network 77
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 76
Regulated expression of amyloidogenic immunoglobulin light chains in mice 75
A case of monoclonal gammopathy of renal significance 75
Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains 73
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 72
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 71
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 70
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 70
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 69
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). 68
Age-related amyloidosis outside the brain: A state-of-the-art review 65
Human wild-type and D76N β2-microglobulin variants are significant proteotoxic and metabolic stressors for transgenic C. elegans 64
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity 64
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 64
Clinical proteomics for diagnosis and typing of systemic amyloidoses 63
Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits 62
Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations 62
A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils 61
Clinical amyloid typing by proteomics: Performance evaluation and data sharing between two centres 59
Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans 58
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 58
Dissecting the molecular features of systemic light chain (Al) amyloidosis: Contributions from proteomics 58
Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. 57
The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis 56
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 56
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 55
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 55
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 54
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 52
Truncation of the constant domain drives amyloid formation by immunoglobulin light chains 48
Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations 48
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 47
Systemic amyloidoses and proteomics: The state of the art 47
The workings of the amyloid diseases. 44
Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing 44
Renal alterations in cats (Felis catus) housed in shelters and affected by systemic AA-amyloidosis: Clinicopathological data, histopathology, and ultrastructural features 43
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 42
AA-amyloidosis in cats (Felis catus) housed in shelters 41
Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration 41
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres 41
Proteomics in protein misfolding diseases. 40
How do we improve treatments for patients with amyloidosis using proteomics? 36
null 35
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders 34
Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis 33
A practical approach to the diagnosis of systemic amyloidoses 29
null 28
The Protein Network in Subcutaneous Fat Biopsies from Patients with AL Amyloidosis: More Than Diagnosis? 17
Renal amyloid‐A amyloidosis in cats: Characterization of proteinuria and biomarker discovery, and associations with kidney histology 16
null 6
Totale 7.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021189 0 0 0 0 0 30 7 60 22 37 28 5
2021/2022308 2 5 2 4 6 2 6 39 20 3 38 181
2022/20231.410 181 116 18 82 120 121 10 59 623 8 32 40
2023/2024585 69 112 33 26 47 123 20 42 9 25 42 37
2024/20251.461 45 107 54 39 32 94 66 65 384 56 199 320
2025/20262.007 279 246 383 444 518 137 0 0 0 0 0 0
Totale 7.210